All In Biotech

Drug Trial Radar · NCT06135415

A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis

A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibulin 10 mg/g Ointment Applied to a Treatment Field Larger Than 25 cm^2 and up to 100 cm^2 in Adult Patients With Actinic Keratosis

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

280

Actual

Start

Dec 21, 2023

Primary completion

Apr 30, 2025

Study completion Nov 25, 2025

Sponsor

Lead sponsor
Almirall, S.A.Industry
Sponsor type
Industry
First posted
Nov 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy and safety of tirbanibulin 10 milligrams per gram (mg/g) ointment when applied to a treatment field (TF) larger than 25 square centimeters (cm\^2) and up to 100 cm\^2 in adult participants with actinic keratosis (AK).

Conditions

  • Keratosis, Actinic

Interventions

  • TirbanibulinDrug

    Participants will apply tirbanibulin ointment topically on the face or balding scalp with AK.

  • Vehicle ointmentOther

    Participants will apply vehicle ointment topically on the face or balding scalp with AK.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Lesion Count at Day 57Time frame: Baseline, Day 57

Locations

35 sites in 5 countries. Site status is shown where the registry gives one.

  • Site 17

    Augsburg, Germany

  • Site 1

    Bad Bentheim, Germany

  • Site 3

    Bochum, Germany

  • Site 18

    Dresden, Germany

  • Site 2

    Hamburg, Germany

  • Site 5

    Hamburg, Germany

  • Site 4

    Mahlow, Germany

  • Site 6

    Wuppertal, Germany

  • Site 24

    Bari, Italy

  • Site 25

    Bologna, Italy

  • Site 19

    Brescia, Italy

  • Site 26

    Cagliari, Italy

  • Site 23

    Florence, Italy

  • Site 22

    Pisa, Italy

  • Site 27

    Reggio Emilia, Italy

  • Site 20

    Roma, Italy

  • Site 21

    Roma, Italy

  • Site 7

    Roma, Italy

  • Site 29

    Heemstede, Netherlands

  • Site 28

    Maastricht, Netherlands

  • Site 31

    Krakow, Poland

  • Site 30

    Ossy, Poland

  • Site 10

    Warsaw, Poland

  • Site 11

    Warsaw, Poland

  • Site 9

    Warsaw, Poland

  • Site 8

    Wroclaw, Poland

  • Site 12

    Barcelona, Spain

  • Site 14

    Barcelona, Spain

  • Site 34

    Barcelona, Spain

  • Site 33

    Granada, Spain

  • Site 13

    Madrid, Spain

  • Site 32

    Salamanca, Spain

  • Site 15

    Valencia, Spain

  • Site 35

    Valencia, Spain

  • Site 16

    Zaragoza, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.